20 results on '"Bal R"'
Search Results
2. Tu1711 A RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF KB174, A NOVEL SYNTHETIC GLYCAN, IN PATIENTS WITH WELL-COMPENSATED CIRRHOSIS
3. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
4. Tu1888 EARLY AND SUSTAINED IMPROVEMENT IN STOOL FREQUENCY AND RECTAL BLEEDING FOLLOWING 52 WEEKS OF MIRIKIZUMAB TREATMENT
5. 1004 – Maintenence Treatment with Mirikizumab, a P19-Directed Il-23 Antibody: 52-Week Results in Patients with Moderately-Toseverely Active Ulcerative Colitis
6. Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial
7. 1004 – Maintenence Treatment with Mirikizumab, a P19-Directed Il-23 Antibody: 52-Week Results in Patients with Moderately-Toseverely Active Ulcerative Colitis
8. Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial
9. Tu1565 – Clinical Utility and Application of Noninvasive Tests of Fibrosis in the Selection of Patients with Advanced Fibrosis Due to Nash in the Phase 2 Atlas Trial
10. 85 - SER-287, an Investigational Microbiome Therapeutic, Induces Remission and Endoscopic Improvement in a Placebo-Controlled, Double-Blind Randomized Trial in Patients with Active Mild-to-Moderate Ulcerative Colitis
11. 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study
12. 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study
13. 85 - SER-287, an Investigational Microbiome Therapeutic, Induces Remission and Endoscopic Improvement in a Placebo-Controlled, Double-Blind Randomized Trial in Patients with Active Mild-to-Moderate Ulcerative Colitis
14. Symptom Severity Influences Drug Efficacy in Women with Diabetic Gastroparesis: Results of a Phase 3 Study with Metoclopramide Nasal Spray
15. Symptom Severity Influences Drug Efficacy in Women with Diabetic Gastroparesis: Results of a Phase 3 Study with Metoclopramide Nasal Spray
16. Tu1980 Correlation of Mucosal MMP9 Expression with Mayo Score and Endoscopic Sub-Score in Patients with Moderately to Severely Active Ulcerative Colitis
17. Tu1945 Clinical Response to Anti-MMP9 Antibody (GS-5745) is Accompanied by Histologic Improvement in Ulcerative Colitis
18. Tu1980 Correlation of Mucosal MMP9 Expression with Mayo Score and Endoscopic Sub-Score in Patients with Moderately to Severely Active Ulcerative Colitis
19. Tu1945 Clinical Response to Anti-MMP9 Antibody (GS-5745) is Accompanied by Histologic Improvement in Ulcerative Colitis
20. Tu2027 - Symptom Severity Influences Drug Efficacy in Women with Diabetic Gastroparesis: Results of a Phase 3 Study with Metoclopramide Nasal Spray
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.